- Home
- NMRA vs KROS Comparison
NMRA vs KROS Comparison
Compare NMRA & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRA | KROS |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.0M | 584.9M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMRA | KROS |
|---|---|---|
| Price | $1.90 | $10.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $7.50 | ★ $21.86 |
| AVG Volume (30 Days) | ★ 1.5M | 248.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.23 | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | ★ N/A | $5.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $10.42 |
| 52 Week High | $3.65 | $22.55 |
Technical Indicators
Market Signals| Indicator | NMRA | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 40.77 | 35.78 |
| Support Level | $1.81 | N/A |
| Resistance Level | $2.22 | $16.12 |
| Average True Range (ATR) | 0.22 | 0.58 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 15.32 | 3.48 |
Price Performance
Historical ComparisonAbout NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.